HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Weighing Rx-to-OTC Switch Of Menopause Treatment

Executive Summary

Novo Nordisk is seeking to switch from Rx-to-OTC status Gina (estradiol hemihydrate), which, if approved, would be the first form of local hormone replacement therapy available without a prescription in the UK.

You may also be interested in...

Rx-to-OTC Switch Of Menopause Treatment Approved In UK

Women in the UK will soon have OTC access to a low-dose Hormone Replacement Therapy drug following the reclassification of Novo Nordisk's Gina.

UK Looks To Switch Overactive Bladder Treatment

Maxwellia is seeking its second first-in-class switch in the UK with an application to reclassify from prescription-only to pharmacy status overactive bladder treatment Aquiette.

HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives

The UK's MHRA has approved the Rx-to-OTC switch of two identical progestogen-only contraceptive pills from HRA Pharma and Maxwellia. Hana and Lovima (both 75mcg desogestrel) will be launched at the end of the month. 


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts